^
No biomarker
Thymic Carcinoma
lenvatinib
Sensitive
:
A1
No biomarker
Thymic Carcinoma
GEM-CAP
Sensitive
:
A2
No biomarker
Thymic Carcinoma
LV5FU2
Sensitive
:
A2
No biomarker
Thymic Carcinoma
CaT
Sensitive
:
A2
KIT mutation
Thymic Carcinoma
sunitinib
Sensitive
:
A2
No biomarker
Thymic Carcinoma
VIP
Sensitive
:
A2
No biomarker
Thymic Carcinoma
EP
Sensitive
:
A2
No biomarker
Thymic Carcinoma
ADOC
Sensitive
:
A2
No biomarker
Thymic Carcinoma
CAP + prednisone
Sensitive
:
A2
No biomarker
Thymic Carcinoma
CAP
Sensitive
:
A2
No biomarker
Thymic Carcinoma
carboplatin
Sensitive
:
A2
No biomarker
Thymic Carcinoma
paclitaxel
Sensitive
:
A2
No biomarker
Thymic Carcinoma
ifosfamide
Sensitive
:
A2
No biomarker
Thymic Carcinoma
etoposide oral
Sensitive
:
A2
No biomarker
Thymic Carcinoma
pembrolizumab
Sensitive
:
A2
No biomarker
Thymic Carcinoma
gemcitabine
Sensitive
:
A2
No biomarker
Thymic Carcinoma
prednisone + octreotide
Sensitive
:
A2
No biomarker
Thymic Carcinoma
octreotide
Sensitive
:
A2
No biomarker
Thymic Carcinoma
everolimus
Sensitive
:
A2
No biomarker
Thymic Carcinoma
pemetrexed
Sensitive
:
A2
EIF4EBP1 expression
Thymic Carcinoma
everolimus
Resistant
:
C3
HER-2 positive
Thymic Carcinoma
pyrotinib
Sensitive
:
C3
HER-2 mutation
Thymic Carcinoma
pyrotinib
Sensitive
:
C3
IGF1R expression
Thymic Carcinoma
everolimus
Resistant
:
C3
VERI is free for non-commercial use, no login needed.
Content on this site is for research purposes only and is not intended  to be a substitute for medical advice.
For commercial access, including additional premium features, please contact us.
By using VERI, you are agreeing to our